The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
Plasma Exchange And Glucocorticoids In Anti-neutrophil Cytoplasm Antibody Associated Systemic Vasculitis: A Randomised Controlled Trial (PEXIVAS Australia)
Funder
National Health and Medical Research Council
Funding Amount
$420,110.00
Summary
ANCA-associated vasculitis is a life-threatening disease. The PEXIVAS trial will investigate whether plasma exchange, in addition to immunosuppressive therapy and glucocorticoids, will reduce death and the development of severe kidney failure due to this disease. Additionally, the project will also look at whether using a reduced dose of glucocorticoids is just as effective as larger doses in lessening the infectious complications of treatment.
The Beta-blocker To LOwer CArdiovascular Dialysis Events (BLOCADE) Feasibility Study
Funder
National Health and Medical Research Council
Funding Amount
$597,811.00
Summary
The BLOCADE Feasibility Study aims to find out what is needed for a study to see if the drug carvedilol reduces heart disease events in people who need kidney dialysis. Carvedilol is widely used to treat the types of heart disease that are common in people on dialysis but the nature of dialysis may lead to more side effects or to less benefit. A Feasibility Study must be done first to properly plan a large study of carvedilol in people on dialysis that answers this important question.
Plasma Exchange And Glucocorticoids In ANCA Associated Vasculitis: A Randomised Controlled Trial (PEXIVAS Australia)
Funder
National Health and Medical Research Council
Funding Amount
$635,243.00
Summary
Vasculitis is a life-threatening disease, and the current treatment for this condition is not satisfactory. This clinical trial aims to determine 1) if plasma exchange can lower mortality and the development of severe kidney failure due to this disease, and 2) if the use of lower doses of corticosteroids can lessen the infectious complications of treatment. This trial is part of a major international effort which will involve a total of 500 patients from Australia, UK, Europe, USA and NZ.
Canadian-Australasian Randomised Trial Of Screening Kidney Transplant Recipients For Coronary Artery Disease (CARSK Study)
Funder
National Health and Medical Research Council
Funding Amount
$1,223,933.00
Summary
Patients waitlisted for kidney transplantation are at increased risk of heart attack and routinely undergo tests every year to screen for heart disease. This may lead to excessive tests, inconvenience, cost and missed opportunities for transplantation. This randomised trial will determine whether such testing is necessary and what it costs to patients and the health system. The results will have implications for tens of thousands of patients worldwide.
I am a nephrologist, clinical epidemiologist and health services researcher aiming to generate high-quality evidence regarding the prevention and management of chronic disease and to reduce disparities in indigenous health.
Understanding And Optimising The Delivery Of Chronic Disease Care For Better Cardiovascular Outcomes
Funder
National Health and Medical Research Council
Funding Amount
$483,402.00
Summary
The proposed research program will undertake research that utilises existing clinical information and structures. This information will provide evidence in a cost effective manner. A particular project will examine current treatment delivered to people with chronic disease. A second project will embed a study of the optimum level of sodium exposure in dialysis within routine clinical practice. The outcome will be a cost-efficient study that will potentially lead to improve outcomes.